Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Ajay Kirtane, MD

Professor of Medicine
Columbia University College of Physicians and Surgeons
New York-Presbyterian Hospital
Chief Academic Officer
Center for Interventional Vascular Therapy
Director
NYP/Columbia Cardiac Catheterization Laboratories
New York, New York

Disclosures

Ajay Kirtane, MD, has the following relevant financial relationships:
Consultant or advisor for: IMDS
Speaker or member of speakers bureau for: Abbott Vascular; Boston Scientific; Chiesi Pharmaceuticals, Inc.; CSI; Medtronic, Inc.; OpSens; Philips Healthcare; ReCor Medical; Regeneron Pharmaceuticals, Inc.; Siemens Healthcare Diagnostics, Inc.; Zoll Medical Corporation
Research funding from: Abbott Vascular; Amgen, Inc.; BIOTRONIK; Bolt Medical; Boston Scientific; Canon; Chiesi Pharmaceuticals, Inc.; CSI; Magenta Medical; Medtronic, Inc.; Merck & Co., Inc.; Neurotronic; Philips Healthcare; ReCor Medical; Shockwave Medical; SoniVie

Dominick J. Angiolillo, MD, PhD

Professor of Medicine
Chief
Division of Cardiology
Medical Director
University of Florida Health Cardiovascular Center
Jacksonville, Florida

Disclosures

Dominick J. Angiolillo, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Abbott Laboratories; Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Biosensors International Group Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Chiesi Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Lilly; Haemonetics Corporation; Janssen Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals; PhaseBio Pharmaceuticals, Inc.; PLx Pharma Inc.; Pfizer, Inc.; Sanofi; Ventura
Research funding from: Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Biosensors International Group Ltd.; CeloNova BioSciences, Inc.; CSL Behring; Daiichi Sankyo, Inc.; Eisai, Inc.; Lilly; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Matsutani Chemical Industry Co., Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals; Osprey Pharmaceuticals USA; RenalGuard Solutions, Inc.

Editor

Asha P. Gupta, PharmD, RPh

Medical Education Director, Medscape, LLC

Disclosures

Asha P. Gupta, PharmD, RPh, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME / ABIM MOC / CE

Selecting the Right Antiplatelet for the Right Patient for the Right Reasons, Part 2: The Answers Analyzed

Authors: Ajay Kirtane, MD; Dominick J. Angiolillo, MD, PhD
CME / ABIM MOC / CE Released: 7/24/2023
Valid for credit through: 7/24/2024, 11:59 PM EST

Start Activity

Credits Available

Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 0.25 ABIM MOC points

Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)

IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for cardiologists, emergency medicine physicians, anesthesiologists, nurses, and pharmacists.

The goal of this activity is for learners to be better able to select the appropriate antiplatelet treatment strategy for patients undergoing PCI.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Current guideline recommendations for antithrombotic use during PCI
- Choosing treatment plans for select patients undergoing PCI in various settings

Disclosures

Faculty

Ajay Kirtane, MD

Professor of Medicine
Columbia University College of Physicians and Surgeons
New York-Presbyterian Hospital
Chief Academic Officer
Center for Interventional Vascular Therapy
Director
NYP/Columbia Cardiac Catheterization Laboratories
New York, New York

Disclosures

Ajay Kirtane, MD, has the following relevant financial relationships:
Consultant or advisor for: IMDS
Speaker or member of speakers bureau for: Abbott Vascular; Boston Scientific; Chiesi Pharmaceuticals, Inc.; CSI; Medtronic, Inc.; OpSens; Philips Healthcare; ReCor Medical; Regeneron Pharmaceuticals, Inc.; Siemens Healthcare Diagnostics, Inc.; Zoll Medical Corporation
Research funding from: Abbott Vascular; Amgen, Inc.; BIOTRONIK; Bolt Medical; Boston Scientific; Canon; Chiesi Pharmaceuticals, Inc.; CSI; Magenta Medical; Medtronic, Inc.; Merck & Co., Inc.; Neurotronic; Philips Healthcare; ReCor Medical; Shockwave Medical; SoniVie

Dominick J. Angiolillo, MD, PhD

Professor of Medicine
Chief
Division of Cardiology
Medical Director
University of Florida Health Cardiovascular Center
Jacksonville, Florida

Disclosures

Dominick J. Angiolillo, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Abbott Laboratories; Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Biosensors International Group Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Chiesi Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Lilly; Haemonetics Corporation; Janssen Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals; PhaseBio Pharmaceuticals, Inc.; PLx Pharma Inc.; Pfizer, Inc.; Sanofi; Ventura
Research funding from: Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Biosensors International Group Ltd.; CeloNova BioSciences, Inc.; CSL Behring; Daiichi Sankyo, Inc.; Eisai, Inc.; Lilly; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Matsutani Chemical Industry Co., Ltd.; Merck & Co., Inc.; Novartis Pharmaceuticals; Osprey Pharmaceuticals USA; RenalGuard Solutions, Inc.

Editor

Asha P. Gupta, PharmD, RPh

Medical Education Director, Medscape, LLC

Disclosures

Asha P. Gupta, PharmD, RPh, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-23-293-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Cardiology

CME / ABIM MOC / CE

Selecting the Right Antiplatelet for the Right Patient for the Right Reasons, Part 2: The Answers Analyzed

Authors: Ajay Kirtane, MD; Dominick J. Angiolillo, MD, PhDFaculty and Disclosures

CME / ABIM MOC / CE Released: 7/24/2023

Valid for credit through: 7/24/2024, 11:59 PM EST

processing....

Earn Credit CME / ABIM MOC / CE Information Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Ajay Kirtane, MD

Dominick J. Angiolillo, MD, PhD

Editor

Asha P. Gupta, PharmD, RPh

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

CME / ABIM MOC / CE

Selecting the Right Antiplatelet for the Right Patient for the Right Reasons, Part 2: The Answers Analyzed

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Ajay Kirtane, MD

Dominick J. Angiolillo, MD, PhD

Editor

Asha P. Gupta, PharmD, RPh

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

Accreditation Statements

For Physicians

For Pharmacists

Instructions for Participation and Credit

Selecting the Right Antiplatelet for the Right Patient for the Right Reasons, Part 2: The Answers Analyzed